Current Strategies for Frontline Therapy in Transplant-Preferred NDMM

Opinion
Video

Panelists discuss how VRd (bortezomib, lenalidomide, dexamethasone) remains the standard frontline regimen for transplant-eligible newly diagnosed multiple myeloma (NDMM) patients, though some now consider adding daratumumab (dara-VRd) in high-risk cases.

Recent Videos
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
5 experts in this video
4 experts in this video
Related Content